Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan

Arcturus Therapeutics Holdings Inc.

2023-Q2 EPS reported -$0.07 revenue$90,804,000

Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).
Cash, equivalents and restricted cash $380.6M at June 30; cash runway extended through early 2026.
ARCT-154 Phase 3 booster met primary endpoint; Meiji Seika Pharma submitted NDA in Japan.
FDA granted Fast Track and Rare Pediatric Disease Designations for ARCT-810 (OTC deficiency).
Regulatory approval received to start ARCT-032 Phase 1b study in cystic fibrosis patients.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arcturus Therapeutics Holdings Inc. reported the second quarter and six months ended June 30, 2023 results: revenue $10.5 million.

Period: the second quarter and six months ended June 30, 2023
Revenue: $10.5 million
Result: reported results

Exact text from the filing

For the three months ended June 30, 2023, we reported revenue of $10.5 million compared with $27.1 million for the three months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-001112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.